Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

Last Close
Feb 29 12:52PM ET
Dollar change
Percentage change
Index- P/E- EPS (ttm)-10.89 Insider Own6.50% Shs Outstand2.74M Perf Week125.73%
Market Cap5.26M Forward P/E- EPS next Y-2.85 Insider Trans0.56% Shs Float2.56M Perf Month139.84%
Income-22.82M PEG- EPS next Q-1.58 Inst Own17.86% Short Float2.53% Perf Quarter30.52%
Sales0.00M P/S- EPS this Y37.21% Inst Trans-16.51% Short Ratio0.20 Perf Half Y-13.57%
Book/sh1.12 P/B1.72 EPS next Y65.05% ROA-120.43% Short Interest0.06M Perf Year-8.20%
Cash/sh1.56 P/C1.23 EPS next 5Y- ROE-178.55% 52W Range0.65 - 6.98 Perf YTD47.59%
Dividend Est.- P/FCF- EPS past 5Y67.79% ROI-937.10% 52W High-72.51% Beta0.67
Dividend TTM- Quick Ratio1.39 Sales past 5Y-25.00% Gross Margin- 52W Low195.64% ATR (14)0.26
Dividend Ex-DateApr 23, 2008 Current Ratio1.39 EPS Y/Y TTM85.30% Oper. Margin0.00% RSI (14)81.17 Volatility16.25% 14.84%
Employees25 Debt/Eq0.00 Sales Y/Y TTM- Profit Margin- Recom1.00 Target Price9.00
Option/ShortNo / No LT Debt/Eq0.00 EPS Q/Q10.47% Payout- Rel Volume894.11 Prev Close0.83
Sales Surprise- EPS Surprise37.80% Sales Q/Q- EarningsNov 13 AMC Avg Volume331.74K Price1.92
SMA20128.24% SMA5082.11% SMA200-9.76% Trades Volume160,777,629 Change130.89%
Today 07:00AM
Feb-26-24 08:00AM
Feb-23-24 08:00AM
Feb-21-24 08:00AM
Jan-03-24 08:00AM
08:52AM Loading…
Dec-29-23 08:52AM
Dec-28-23 08:00AM
Dec-27-23 08:00AM
Dec-20-23 08:00AM
Dec-05-23 08:00AM
Nov-29-23 08:00AM
Nov-27-23 08:00AM
Nov-24-23 08:00AM
Nov-13-23 04:01PM
Oct-31-23 08:00AM
08:00AM Loading…
Oct-20-23 08:00AM
Oct-18-23 08:00AM
Oct-11-23 08:00AM
Oct-03-23 08:00AM
Sep-27-23 08:00AM
Sep-20-23 08:00AM
Sep-18-23 08:00AM
Sep-11-23 08:00AM
Sep-05-23 08:00AM
Aug-30-23 08:00AM
Aug-28-23 11:04AM
Aug-24-23 08:00AM
Aug-21-23 08:00AM
Aug-14-23 08:00AM
Jul-24-23 08:00AM
08:00AM Loading…
Jul-17-23 08:00AM
Jun-26-23 08:00AM
Jun-12-23 08:00AM
Jun-07-23 08:00AM
Jun-05-23 08:00AM
May-30-23 08:00AM
May-24-23 08:00AM
May-22-23 08:00AM
May-19-23 08:00AM
May-18-23 08:00AM
May-15-23 09:25AM
May-02-23 07:30AM
Apr-10-23 07:30AM
Apr-03-23 04:05PM
Mar-23-23 07:30AM
Mar-21-23 07:33AM
Mar-14-23 07:30AM
Feb-28-23 07:30AM
Feb-23-23 07:33AM
Feb-22-23 07:33AM
Feb-01-23 07:33AM
Dec-21-22 07:30AM
Nov-28-22 07:30AM
Nov-16-22 07:30AM
Nov-01-22 07:30AM
Oct-24-22 07:00AM
Oct-12-22 08:00AM
Aug-31-22 07:30AM
Jul-27-22 07:30AM
Jul-26-22 05:30PM
Jul-25-22 08:00AM
Jul-19-22 07:30AM
Jul-14-22 12:15PM
Jul-13-22 07:30AM
Jun-08-22 07:30AM
May-24-22 04:05PM
May-17-22 07:30AM
May-11-22 07:30AM
May-05-22 07:30AM
May-03-22 05:13PM
Apr-29-22 08:35AM
Apr-25-22 08:35AM
Apr-06-22 07:30AM
Mar-31-22 05:02PM
Mar-29-22 07:30AM
Mar-15-22 07:30AM
Mar-03-22 07:30AM
Mar-01-22 07:30AM
Feb-17-22 07:30AM
Feb-15-22 04:05PM
Feb-11-22 08:30AM
Feb-08-22 04:45PM
Jan-18-22 07:30AM
Jan-06-22 04:01PM
Dec-06-21 07:30AM
Nov-29-21 07:30AM
Nov-18-21 07:30AM
Nov-09-21 07:09AM
Nov-08-21 07:30AM
Oct-26-21 07:30AM
Oct-18-21 08:35AM
Oct-15-21 12:52PM
Oct-11-21 09:25AM
Oct-07-21 07:30AM
Oct-05-21 07:30AM
Sep-20-21 07:00AM
Sep-17-21 07:00AM
Sep-09-21 07:30AM
Aug-18-21 08:00AM
Enveric Biosciences, Inc. develops cannabinoid medicines and combination therapies. It is a patient-centric biotechnology company endeavouring to enhance the lives of those who are adversely affected by the side effects of Cancer Treatments. The firm is testing natural compounds, starting with cannabinoids to provide patients and clinicians with novel prescription medicines to serve these unmet medical needs. The company is headquartered in Naples, FL.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
PASQUALONE FRANKDirectorSep 15Buy2.141,0002,1401,000Sep 19 05:34 PM